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King Sau
osting by EAbstract A sensitive ﬁrst derivative spectroﬂuorimetric method (1D-spectroﬂuorimetry) was devel-
oped for the determination of mirtazapine. Calibration graph for mirtazapine determination was
established using the ﬁrst derivative amplitudes of the mirtazapine emission spectrum
(kex = 314 nm) in 0.1 M sulphuric acid measured at 375–435 nm from peak to peak, as the analyt-
ical signals. Moreover, the ratio of 1D-spectrophotometric peak amplitudes at these wavelengths
was calculated and used for the detection of the presence of interferences. Linearity range was found
to be between 1 and 40 ng ml1 with correlation coefﬁcient (r) = 0.9999. The limit of quantitation
(LOQ) was 1.0 ng ml1 and the limit of detection (LOD) was 0.2 ng ml1. The proposed method
was validated according to ICH; and it has been applied for the drug determination in human
plasma without prior extraction and in tablets. The proposed method’s accuracy, reproducibility,
selectivity and simplicity suggest its application in quality control analysis of the drug.
ª 2010 King Saud University. All rights reserved.1. Introduction
Mirtazapine (MIR); (Fig. 1) [1,2,3,4,10,14b-Hexahydro-2-
methylpyrazino-[2,1a] pyrido [2,3-c] (Baldwin et al., 2005)
benzazepine] is a recent second generation antidepressant.
Chemically, MIR is a piperazinoazepine compound which
belongs to the class of noradrenergic and speciﬁc serotonergic
antidepressants (NaSSA) and its mechanism of actionity. All rights reserved. Peer-
d University.
lsevierprobably involves the increased release of serotonin and nor-
epinephrine due to the antagonism on auto-receptors and
a2-adrenergic hetero-receptors. This mechanism, which differs
from that of most second generation antidepressants, grants
good efﬁcacy in the treatment of patients who are non-respon-
der to the latter (Gillman, 2006). The drug is currently used
against generalized anxiety disorder (Baldwin et al., 2005)
obsessive–compulsive disorder (Goodnick et al., 1999) and
post traumatic stress disorder (Koran et al., 2005). MIR also
shows promise in preventing post-chemotherapy nausea and
vomiting due to its anti-emetic effects (Kast, 2007).
MIR is available as ﬁlm-coated tablets; the initial dose is
15–30 mg day1, which can be increased according to the ther-
apeutic efﬁcacy and the needs of the patient (Mandrioli et al.,
2006). Typical plasma levels corresponding to these daily doses
are in the 30–80 ng ml1 range. Since the plasma half-life of
MIR is about 20 h, it is usually taken once daily, immediately
before going to sleep (Gillman, 2006).
Figure 1 Chemical structure of mirtazapine.
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performance liquid chromatography (Zhai et al., 2005; De San-
tana and Bonato, 2008; Hong et al., 2008), gas chromatography
(Sanchez De La Torre et al., 2005), capillary electrophoresis
(Aturki et al., 2007) and HPTLC (Reddy and Devi, 2008). Ana-
lytical methods have been described for the determination of
MIR in pharmaceutical formulations. These methods include:
UV spectrophotometric method (Karasen and Altinoz, 2000),
spectroﬂuorimetric method (Labat et al., 2002) and time con-
suming HPLC and capillary zone electrophoresis (CZE) proce-
dures Labat et al., 2002. Review of the literature revealed that,
up to the present time, nothing has been published concerning
the determination of MIR in plasma by spectroﬂuoriometry.
The aim of this work was to develop a validated, sensitive,
simple and time saving ﬁrst derivative spectroﬂuorimetric
method (1D-spectroﬂuorimetry) for the determination of mirt-
azapine in spiked human plasma and in commercial tablets.
2. Experimental
2.1. Materials and reagents
MIR was kindly supplied as a gift sample by Organon, OSS,
used without further puriﬁcation. All reagents used were of
analytical grade. The pharmaceutical formulation analyzed
was Remeron tablets (Batch No. 494077) labelled to contain
30 mg MIR and other excipients [maize starch, hydroxypropyl
cellulose, magnesium stearate, colloidal silicone dioxide, lac-
tose, hydroxypropyl methyl cellulose, polyethyleneglycol
8000, titanium dioxide {E171} and yellow iron oxide {E172}
and red iron oxide {E172}].
2.2. Apparatus
Fluorescence measurements were carried out using a Shimadzu
(Kyoto, Japan) RF-1501 version 3.0 spectroﬂuorophotometer
equipped with a 150 W xenon lamp and 1-cm quartz cells.
2.3. Solutions
Stock solution (10 lg ml1) was prepared by dissolving appro-
priate amounts of MIR in methanol. Working solution of
100 ng ml1 was prepared by diluting the stock solution of
MIR with 0.1 M H2SO4.
2.4. Procedures
2.4.1. Construction of calibration curve
Standard solutions were prepared by diluting the working
solution to the concentrations of 1, 5, 10, 20, 40 ng ml1 in
0.1 M H2SO4. Then, the ﬁrst derivative (
1D) amplitudes ofemission spectrum (kex = 314 nm) at 375–435 nm from peak
to peak were measured and plotted against the concentrations
of MIR to give a linear relationship.
2.4.2. Procedure for tablets
Ten tablets were accurately weighed and powdered. A sample
equivalent to one tablet was weighed and transferred to a
50 ml volumetric ﬂask. Thirtymillilitres ofmethanolwere added
and the ﬂask sonicated for 30 min, then completed to the volume
with methanol; and the solution was ﬁltered. After ﬁltration,
appropriate dilutions were made in the range of 1–40 ng ml1
with 0.1 MH2SO4. Then, the procedure was completed as men-
tioned under construction of calibration curve; starting from
then, the ﬁrst derivative (1D) amplitudes of emission spectrum.
2.4.3. Procedure for human plasma
Plasma sample (0.5 ml) was transferred into a series of centrifu-
gation tubes. Aliquots of MIR standard methanolic solution
were added to each tube and stir for 3 min, so that the ﬁnal con-
centration of the drug was in the range 50–100 ng ml1. Two
millilitres of methanol was added for deproteination. Tubes
were mixed well and centrifuged for 5 min. The protein-free
supernatants were transferred to 15-ml test tubes and evapo-
rated under a gentle stream of nitrogen to dryness. The inside
wall of test tubes were washed down with 2 ml methanol, then
the whole contents of the test tubes were evaporated to dryness
under nitrogen. The residues were dissolved in 0.5 ml methanol
and complete to 5 ml with 0.1 M H2SO4 and these solutions
were transferred quantitatively into 25-ml measuring ﬂasks
and completed to the mark using 0.1 M H2SO4. The ﬁrst deriv-
ative amplitudes of emission spectrum (kex = 314 nm) were
measured at (375–435 nm) from peak to peak. Recovery and
quantiﬁcation of MIR were performed by mean of both cali-
bration curve and standard addition methods (Table 4).3. Results and discussion
Upon dissolving MIR in 0.1 M sulphuric acid, a native strong
ﬂuorescence was observed. Scanning the emission spectrum
showed kem at 415 nm upon excitation at 314 nm, the ﬁrst
derivative amplitudes of emission spectrum were measured at
(375–435 nm) from peak to peak (Fig. 2). This may be attrib-
uted to the high conjugation.
The ﬁrst derivative spectroﬂuorimetric method (1D-spectro-
ﬂuorimetry) is highly sensitive, so it allows the determination
of MIR in plasma where linear correlation was achieved in
concentration range 1–40 ng ml1. Moreover, the ratios of
1D-spectra peak amplitudes at these wavelengths were calcu-
lated and used for the detection of the presence of interferences
(Bonazzi et al., 1997). The ratios of the 1D-values for different
concentrations of MIR standard solutions and pharmaceutical
formulation are presented in Table 1. Its concentration inde-
pendent and of reasonable reproducibility. Furthermore, it is
speciﬁc for the drug and can be used for its identiﬁcation as
well as for testing its purity.
Different solvents as methanol, water, acetonitrile and buf-
fer solutions were tried. 0.1 M sulphuric acid was found to be
the best solvent that gave high emission intensity.
The main instrumental parameter affecting the shape of
derivative emission spectra is the wavelength increment over
which the derivative spectrum is obtained (Dk). This param-
Table 1 Ratios of 1D-spectrophotometric peak amplitudes for
different concentrations of mirtazapine.
Concentration
(ng ml1)
1D375 nm/
1D435 nm
bulk powder
Tabletsa
1 1.45 1.49
3 1.47 1.47
5 1.44 1.46
10 1.46 1.47
40 1.43 1.44
Mean 1.45 1.46
SD 0.016 0.015
RSD% 1.09 1.03
a Remeron (30 mg mirtazapine per tablet) Batch No. 94077.
Figure 2 The excitation ( ), the emission ( ) and the ﬁrst
derivative of emission (- Æ Æ - Æ Æ -) spectra of 40 ng ml1 in 0.1 M
H2SO4 using Dk= 10 nm.
Table 2 Statistical data of the regression equation for the
determination of mirtazapine by the proposed method.
Parameters 1D-spectroﬂuorimetric
method
Dk 10 nm
Concentration range (ng ml1) 1–40
Intercept (a) 2.78
Slope (b) 16.23
Correlation coeﬃcient (r) 0.9999
Standard deviation of intercept (Sa) 2.21
Standard deviation of slope (Sb) 11.86 · 102
Variance around the slope ðS2bÞ 1.41 · 102
Relative standard deviation of slope (Sb%) 73.00 · 102
a/Sa
a 1.26
Limit of detection (LOD) (ng ml1) 0.20
Limit of quantitation (LOQ) (ng ml1) 1.00
a Theoretical value of t (a/Sa) = 2.31 at 0.05 level of signiﬁcance
for a number of sample = 5.
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peak, good selectivity, and increased sensitivity for the deter-
mination (El-Gindy et al., 2002). Generally, the noise level
decreases with an increase in Dk, thus decreasing the ﬂuctu-
ation in the derivative spectrum. However, if the value of Dk
is too large, the spectral resolution is very poor. Therefore,
the optimum value of Dk should be determined by taking
into account the noise level and the resolution of the
spectrum. Some values of Dk were tested, and Dk= 10 nm
was selected for the 1D-spectroﬂuorimetric measurement as
the optimal condition to give a satisfactory signal-to-noise
ratio.3.1. Validation of methods
3.1.1. Linearity
The linearity of the proposed methods was evaluated by ana-
lyzing series of different concentrations of MIR. According
to ICH (Q2A, 2005), at least ﬁve concentrations must be used.
Under the above described experimental conditions, the
calibration curve of the 1D-spectroﬂuorimetric peak ampli-
tudes (from peak to peak) at the speciﬁed wavelengths versus
certain MIR concentration ranges (Table 2) is linear. Slope,
intercept, correlation coefﬁcient, standard deviation of slope
and intercept (obtained by the linear least squares treatment
of the results) are also given in Table 2. The value for the cor-
relation coefﬁcient was not sufﬁcient to evaluate the linearity
of the calibration graph. So, the linearity was evaluated by cal-
culation of the relative SD of the slope (Sb%) Torrado et al.,
1994. Also, the small degree of scatter of the experimental data
point around the line of regressions was conﬁrmed by the small
values of the variances around the slopes S2b. For more conﬁr-
mation, the Student’s t-test was performed to determine
whether the experimental intercept (a) of the above-mentioned
regression lines was not signiﬁcantly different from the null
hypothesis. The calculated values of t (a/Sa) Morelli, 1988 do
not exceed the 95% criterion of t= 2.31 for 5 samples. So
the intercepts are not signiﬁcantly different from zero. Thus,
the hypothesis that (a) is of negligible value is conﬁrmed.
3.1.2. Accuracy and precision
The accuracy study was performed by addition of known
amounts of MIR to known concentration of the commercial
capsules (standard addition method). The resulting mixtures
were assayed and results obtained for MIR addition method
suggests good accuracy of the proposed methods and no inter-
ference from capsule’s excipients, hence proposed method was
applicable for the quantitative determination of MIR in its
dosage form.
The intra-day and inter-day variation for the determination
of MIR were carried out at three different concentration levels
namely; 1, 20 and 40 ng ml1. Method repeatability was ob-
tained from RSD% values obtained by repeating the assay ﬁve
times on the same day for intra-day precision (Table 3). Inter-
Table 3 Precision and robustness of proposed method using
average of three different concentration levels (1, 20 and
40 ng ml1) of mirtazapine.
Parameters SD of peak
amplitudes
RSD%
Precision
Intra-day precision 6.03 1.84
Inter-day precision 5.50 1.68
Robustness
Solvents of diﬀerent Sources 5.80 1.77
Diﬀerent molarity of sulphuric acid
(0.05 M, 0.1 M, 0.15 M)
5.00 1.53
The wavelength increment over which the
derivative spectrum was obtained (Dk)
(9,10 and 11)
4.80 1.47
Table 4 Statistical comparison for the determination of
mirtazapine in its tablets by the proposed method and that of
USP-compendial one.
Preparation Mean found ± RSD%a
1D-spectroﬂu-
orimetry
Oﬃcial methodb
Remeron tablets (30 mg
mirtazapine per tablet) Batch
No. 494077
99.94 ± 0.69 100.90 ± 1.52
tc 1.27
Fc 4.85
Recoveryd 100.50 ± 1.20
a Percentage relative standard deviation for ﬁve determinations,
Percentage recovery from the label claim amount.
b HPLC (United States Pharmacopeia 30, 2007).
c Theoretical values of t and F for p= 0.05 are 2.31 and 6.39,
respectively.
d For standard addition of different concentrations of MIR.
48 R.M. Youssefmediate precision was assessed by the assay of the sample sets
on three different days (inter-day precision). The calculated
RSD% are mentioned in Table 3. The results indicated satis-
factory precision of the proposed methods.
3.1.3. Detection and quantitation limits
According to ICH recommendations (Q2A, 2005) the ap-
proach based on the SD of the response and the slope was used
for determining the detection and quantitation limits. The the-
oretical values were assessed practically and given in Table 2.
3.1.4. Robustness
Robustness of the proposed method was evaluated by analyz-
ing MIR at three different concentration levels, as used under
the evaluation of precision. This was performed under inten-
tional slight variation of the selected parameters. The parame-
ters studied were, solvents of different lots, different molarities
of sulphuric acid and the wavelength increment over which the
derivative spectrum is obtained (Dk). It was found that varia-
tion in the above parameters had no signiﬁcant inﬂuence on
the determination of MIR using proposed method. The low
values of RSD% of the ﬁrst derivative amplitudes of emission
spectrum along with nearly unchanged kex or kem of MIR ob-
tained after introducing small deliberate changes in the method
parameters indicated the robustness of the developed 1D-spec-
troﬂuorimetric method (Table 3).
3.1.5. Application
3.1.5.1. Assay of commercial tablets. Using the proposed meth-
od, assay of MIR in its tablets was carried out as described
under tablet preparation in the experimental section. Five
replicate determinations were made. Satisfactory results were
obtained in a good agreement with the label claims (Table 4).
These results were compared with ofﬁcial method ( United
States Pharmacopeia 30, 2007). Statistical comparison of the
results was performed with regard to accuracy and precision
using Student’s t-test and the F-ratio at 95% conﬁdence level
(Table 4). There is no signiﬁcant difference between the
proposed method and ofﬁcial HPLC method with regard to
accuracy and precision.
3.1.5.2. Determination of drug in spiked human plasma. The
spectroﬂuorimetric method was applied to the analysis of plas-
ma samples, fortiﬁed with varying amounts of MIR (5–40 ng
per 1 ml), after methanolic extraction procedure. The recover-ies of MIR were calculated with reference to standard MIR of
the same theoretical concentrations in methanol. The recover-
ies varied between 92% and 95%, i.e. a 5–8% of error in de-
fect. Further trials for the analysis of MIR in plasma
samples using standard addition procedure were performed.
Recovery ranged from 97% to 99% and RSD ranged from 1
to 3 were obtained. Accordingly, the preliminary results in
spiked plasma samples suggest that this methodology may also
has application in the assay of the drug in biological ﬂuids
especially plasma.
4. Conclusion
A simple, rapid and sensitive method has been developed for
the determination of mirtazapine in plasma and formulation.
The proposed method has distinct advantages over other exist-
ing methods regarding selectivity, sensitivity and minimum
detectability, moreover, it can be applied to the determination
of drug in spiked human plasma without prior treatment. The
evaluation of the 1D-spectroﬂuorimetric method towards the
analysis of real plasma samples (in vivo study) and establish-
ment of effective extraction procedure to separate different
metabolites should be the matter of interest in the future.
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